Lonardi, Sara http://orcid.org/0000-0002-7593-8138
Prete, Alessandra Anna
Morano, Federica
Messina, Marco
Formica, Vincenzo
Corsi, Domenico Cristiano
Orciuolo, Corrado
Frassineti, Giovanni Luca
Zampino, Maria Giulia
Casagrande, Mariaelena
Masi, Gianluca
Ronzoni, Monica
Scartozzi, Mario
Buonadonna, Angela
Mosconi, Stefania
Ratti, Margherita
Sartore-Bianchi, Andrea
Tamburini, Emiliano
Prisciandaro, Michele
Bergamo, Francesca
Spada, Massimiliano
Corallo, Salvatore
Vettore, Valentina
Loupakis, Fotios
Fassan, Matteo
Del Bianco, Paola
Zagonel, Vittorina
Pietrantonio, Filippo
Clinical trials referenced in this document:
Documents that mention this clinical trial
How I treat anal squamous cell carcinoma
https://doi.org/10.1136/esmoopen-2020-000711
Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: the CARACAS study
https://doi.org/10.1136/jitc-2021-002996
Documents that mention this clinical trial
How I treat anal squamous cell carcinoma
https://doi.org/10.1136/esmoopen-2020-000711
Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: the CARACAS study
https://doi.org/10.1136/jitc-2021-002996
Documents that mention this clinical trial
Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: the CARACAS study
https://doi.org/10.1136/jitc-2021-002996
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer
https://doi.org/10.1136/jitc-2022-006658
Funding for this research was provided by:
Merck Serono
Gruppo Oncologico Nord Ovest (GONO) foundation